Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Celcuity Inc.
Celcuity Inc. News
Celcuity Inc. Quantitative Score
About Celcuity Inc.
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
Celcuity Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Celcuity Inc. Financials
Table Compare
Compare CELC metrics with: | |||
|---|---|---|---|
Earnings & Growth | CELC | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | CELC | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | CELC | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | CELC | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Celcuity Inc. Income
Celcuity Inc. Balance Sheet
Celcuity Inc. Cash Flow
Celcuity Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Buy |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Celcuity Inc. Executives
| Name | Role |
|---|---|
| Mr. Brian F. Sullivan | Co-Founder, Chairman & Chief Executive Officer |
| Dr. Lance G. Laing Ph.D. | Co-Founder, Chief Science Officer, Vice President, Secretary & Director |
| Ms. Vicky Hahne CPA | Chief Financial Officer |
| Mr. Brent Eilefson | General Counsel |
| Mr. Igor Gorbatchevsky M.D. | Chief Medical Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Brian F. Sullivan | Co-Founder, Chairman & Chief Executive Officer | Male | 1962 | 838.17K |
| Dr. Lance G. Laing Ph.D. | Co-Founder, Chief Science Officer, Vice President, Secretary & Director | 1962 | 441.28K | |
| Ms. Vicky Hahne CPA | Chief Financial Officer | Female | 1966 | 413.65K |
| Mr. Brent Eilefson | General Counsel | Male | -- | |
| Mr. Igor Gorbatchevsky M.D. | Chief Medical Officer | Male | -- |
Celcuity Inc. Insider Trades
| Date | 27 May |
| Name | Buller Richard E |
| Role | Director |
| Transaction | Disposed |
| Type | G-Gift |
| Shares | 1079 |
| Date | 27 May |
| Name | Buller Richard E |
| Role | Director |
| Transaction | Acquired |
| Type | G-Gift |
| Shares | 1079 |
| Date | 28 May |
| Name | Buller Richard E |
| Role | Director |
| Transaction | Disposed |
| Type | G-Gift |
| Shares | 6522 |
| Date | 28 May |
| Name | Buller Richard E |
| Role | Director |
| Transaction | Acquired |
| Type | G-Gift |
| Shares | 6522 |
| Date | 24 Jun |
| Name | Murphy Polly A. |
| Role | Director |
| Transaction | Disposed |
| Type | G-Gift |
| Shares | 16300 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 27 May | Buller Richard E | Director | Disposed | G-Gift | 1079 |
| 27 May | Buller Richard E | Director | Acquired | G-Gift | 1079 |
| 28 May | Buller Richard E | Director | Disposed | G-Gift | 6522 |
| 28 May | Buller Richard E | Director | Acquired | G-Gift | 6522 |
| 24 Jun | Murphy Polly A. | Director | Disposed | G-Gift | 16300 |